Shots:

• The US FDA has put a partial clinical hold on P-II/III study of Inovio’s INO-4800- including its CELLECTRA 2000 delivery device to be used in the trial because it has additional questions about the trial
• Inovio is actively working to address the FDA's questions and plans to respond in Oct’2020 after which the FDA will have ~30 days to notify the company about its decision as to proceed the trial or no
• Additionally- the partial clinical hold does not impact the advancement of Inovio’s other product candidates in development

­ Ref: PRNewswire | Image: GMP News